Pulmonary fibrosis is a chronic progressive lung disease that steadily leads to lung
architecture disruption and respiratory failure. The development of pulmonary fibrosis is …

Animal models remain invaluable for study of respiratory diseases, however, translation of
data generated in genetically homogeneous animals housed in a clean and well-controlled …

Interleukin-11 (IL-11) is a profibrotic cytokine essential for the differentiation of fibroblasts
into collagen-secreting, actin alpha 2, smooth muscle–positive (ACTA2+) myofibroblasts …

Idiopathic pulmonary fibrosis (IPF) is a fatal and incurable form of interstitial lung disease in
which persistent injury results in scar tissue formation. As fibrosis thickens, the lung tissue …

Cellular senescence, a persistent state of cell cycle arrest, accumulates in aged organisms,
contributes to tissue dysfunction, and drives age-related phenotypes. The clearance of …

Large multicenter clinical trials have led to two recently approved drugs for patients with
idiopathic pulmonary fibrosis (IPF); yet, both of these therapies only slow disease …

The tyrosine kinase inhibitor nintedanib (BIBF 1120) is in clinical development for the
treatment of idiopathic pulmonary fibrosis. To explore its mode of action, nintedanib was …

Interstitial lung disease (ILD) comprises a large number of chronic lung disease
characterized by varying degrees of inflammation and fibrosis. Mostly they are idiopathic …

The incidence and prevalence of pathological fibrosis increase with advancing age,
although mechanisms for this association are unclear. We assessed the capacity for repair …

The pathogenesis of lung fibrosis involves hyperactivation of innate and adaptive immune
pathways that release inflammatory cytokines and growth factors such as tumor growth …